Hemady generic
Hemady is a pharmaceutical drug owned by Dexcel Pharma. It contains dexamethasone as its active ingredient and was first authorized for market use on October 3, 2019. It has a total of 2 patents, none of which have expired.
When will Hemady generic be available?
The generic version of Hemady is anticipated to be available after December 18, 2037, upon the expiry of the last patent.
Hemady uses
Hemady is used for the treatment of adults with multiple myeloma. It's effectiveness comes from its active ingredient, dexamethasone, which is used in combination with an anti-myeloma product.
Hemady patent expiration
Hemady holds a total of 2 patents. The last patent of Hemady is due to expire on December 18, 2037, making it possible for the release of Hemady generics. Below are the details of the patents: